Navigation Links
Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015)
Date:5/29/2015

Los Gatos, CA (PRWEB) May 29, 2015

GeneWEAVE, Inc., a clinical diagnostics company addressing multi-drug-resistant organisms (MDROs), announced that initial feasibility data supporting the use of Smarticles™ technology for same-shift bacterial detection and susceptibility testing from positive blood cultures will be presented at asm2015 on May 31, 2015 in New Orleans, LA. The Company’s Smarticles™ technology is a new class of molecular diagnostics that can quickly detect bacteria and assess antibiotic susceptibility directly from clinical samples without the need for sample preparation or organism isolation. The data being presented demonstrates that assays developed with Smarticles™ technology were able to analyze Gram-positive and Gram-negative bacteria for susceptibility to multiple classes of antibiotics as well as determine antibiotic susceptibility of a target pathogen directly from a polymicrobial positive blood culture sample matrix within 4 hours without the need for complex sample preparation.

The data will be presented on Sunday, May 31, 2015 from 10:45AM – 12:00PM in Session 014, Antimicrobial Resistance and Susceptibility Testing: Gram-Positive (Division C). The Company will also be exhibiting at Booth #143 during the meeting at the New Orleans Ernest N. Morial Convention Center and will host a Satellite Symposium at the JW Marriott New Orleans Hotel on June 1 featuring Lance R. Peterson, MD, Director of Microbiology and Infectious Diseases Research at NorthShore University HealthSystem.

“Knowing the most appropriate antibiotic to use for each individual patient’s infection is becoming more important as the levels of antibiotic resistance continue to increase worldwide. Receiving this information quickly is crucial for better patient outcomes - and in sepsis, decreasing time to appropriate treatment is a key component to reducing mortality,” said Steve Tablak, CEO at GeneWEAVE. “The data from this study supports how our Smarticles™ technology can deliver more timely susceptibility results. We are pleased with the growing evidence that supports the application of our transformative Smarticles™ technology for use in an application as important as sepsis.”

The emergence and spread of bacteria that are resistant to currently available antibiotics is a growing worldwide threat recently highlighted by multiple public health agencies including the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC). Antibiotic resistance is further complicating the treatment of infectious diseases where time is of the essence. Easy-to-use diagnostic tests that quickly identify which antibiotics will be effective for a specific infection are needed for better patient outcomes. Obtaining this data via current methods is time-consuming and labor-intensive, taking days to deliver the time-critical antibiotic susceptibility information that healthcare providers need. GeneWEAVE is using Smarticles™ technology to develop direct-from-sample susceptibility tests that will quickly rule-in appropriate antibiotic therapy within hours, so that healthcare providers will know the best treatment to use at the earliest possible moment.

About GeneWEAVE
GeneWEAVE, Inc., based in Los Gatos, Calif., is a privately-held in vitro diagnostics company that is advancing clinical microbiology with diagnostic solutions to aid healthcare providers in the fight against drug-resistant bacteria by enabling impactful surveillance programs, early therapy guidance and successful antibiotic stewardship. The company’s innovative and proprietary Smarticles™ technology harnesses the power of biology to rapidly detect drug resistance and measure susceptibility information without the need for enrichment, culture, or sample preparation. We call this new paradigm, “Sample-In/Susceptibility-Out.”

GeneWEAVE and Smarticles are trademarks of GeneWEAVE, Inc. All rights reserved.

Read the full story at http://www.prweb.com/releases/2015/05/prweb12748227.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. SACHEM Booth #1441 At SEMICON Europa Oct 8-10th, Highlighting Envure System™
2. NYCEDC Announces Winners of Innovate Health Tech, Highlighting Innovation in NYCs Healthcare Sector
3. Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment
4. Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers
5. GeneWEAVE Presents Data for Smarticles™ Assay Targeted Towards Carbapenem-Resistant Enterobacteriaceae (CRE)
6. Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024
7. Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies
8. PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy
9. Cubresa Launches Simultaneous PET/MRI Technology
10. Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players.
11. Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... The ... hobbyists, and the University Aviation Association (UAA), the unifying voice for collegiate aviation ... Challenge will encourage teamwork, competition, and success through a STEM-based education platform. , ...
(Date:6/22/2017)... ... 21, 2017 , ... Building on the success of the inaugural RAADfest last ... very latest developments in radical life extension. RAADfest combines cutting edge science presented for ... of personal development, making it the largest most comprehensive and inclusive super longevity event ...
(Date:6/22/2017)... ... June 22, 2017 , ... For the ... has produced a Spotlight series on “Cell Therapy Regulation” for its ... leading experts on the unique regulatory challenges of stem cell medical research. , ...
(Date:6/22/2017)... Frederick, MD (PRWEB) , ... June 22, 2017 ... ... software solutions provider, announced the release of Limfinity® version 6.5, a content-packed update ... Limfinity® framework continue to gain a larger and more diverse base of customers ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):